All In Biotech

Drug Trial Radar · NCT07000136

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

473

Actual

Start

Jun 10, 2025

Primary completion

Jan 4, 2027

Study completion Jan 4, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Conditions

  • Heterozygous Familial Hypercholesterolaemia

Interventions

  • AZD0780Drug

    Participants will receive daily oral dose of AZD0780

  • PlaceboDrug

    Participants will receive daily oral dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in LDL-C from baseline to 12 weeksTime frame: Baseline - 12 weeks

Locations

133 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Garden Grove, California

  • Research Site

    San Diego, California

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Peachtree Corners, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Hammond, Louisiana

  • Research Site

    Las Vegas, Nevada

  • Research Site

    New York, New York

  • Research Site

    Morganton, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Lima, Ohio

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Humble, Texas

  • Research Site

    Kingwood, Texas

  • Research Site

    McAllen, Texas

  • Research Site

    Mesquite, Texas

  • Research Site

    Redmond, Washington

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad Autonoma de Bs As, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Melbourne, Australia

  • Research Site

    Campinas, Brazil

  • Research Site

    São Caetano do Sul, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Chicoutimi, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.